Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 07.11.16 in Vol 5, No 4 (2016): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)"

Nobuko Yamaguchi, Sonoko Misawa, Yasunori Sato, Kengo Nagashima, Kanako Katayama, Yukari Sekiguchi, Yuta Iwai, Hiroshi Amino, Tomoki Suichi, Takanori Yokota, Yoichiro Nishida, Nobuo Kohara, Koichi Hirata, Kazutoshi Nishiyama, Ichiro Yabe, Ken-Ichi Kaida, Norihiro Suzuki, Hiroyuki Nodera, Shoji Tsuji, Haruki Koike, Jun-Ichi Kira, Hideki Hanaoka, Susumu Kusunoki, Satoshi Kuwabara, JET-GBS Group

JMIR Res Protoc 2016 (Nov 07); 5(4):e210 

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6610):

(note that this is only a small subset of citations)

  1. Kuwahara M, Kusunoki S. Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy. Clinical and Experimental Neuroimmunology 2018;9(1):65
    CrossRef
  2. Misawa S, Suichi T. Guillain‐Barré syndrome: Novel treatment by complement inhibition. Clinical and Experimental Neuroimmunology 2020;11(2):90
    CrossRef
  3. Uncini A, Vallat J. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. Journal of Neurology, Neurosurgery & Psychiatry 2018;89(6):627
    CrossRef
  4. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Human Vaccines & Immunotherapeutics 2018;:1
    CrossRef
  5. Keller CW, Quast I, Dalakas MC, Lünemann JD. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. Journal of Neuroimmunology 2019;330:23
    CrossRef
  6. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Nagashima T, Shimizu T, Hirotani M, Kadoya M, Nakahara J, Shimizu J, Tanaka M, Sobue G, Katsuno M, Yamaguchi H, Ogata H. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519
    CrossRef
  7. Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2020;2020(1)
    CrossRef
  8. Pilch KS, Spaeth PJ, Yuki N, Wakerley BR. Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Review of Neurotherapeutics 2017;17(6):579
    CrossRef
  9. Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Ikeda S, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. Markers for Guillain‐Barré syndrome with poor prognosis: a multi‐center study. Journal of the Peripheral Nervous System 2017;22(4):433
    CrossRef
  10. Wijdicks EF, Klein CJ. Guillain-Barré Syndrome. Mayo Clinic Proceedings 2017;92(3):467
    CrossRef
  11. . Development of new treatments with drug repositioning strategies: POEMS and Guillain‐Barré syndrome. Neurology and Clinical Neuroscience 2021;9(1):50
    CrossRef
  12. Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 2022;19(3):874
    CrossRef
  13. Momenzadeh S, Jami M. Remyelination in PNS and CNS: current and upcoming cellular and molecular strategies to treat disabling neuropathies. Molecular Biology Reports 2021;48(12):8097
    CrossRef
  14. . Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome. Neurotherapeutics 2022;19(3):885
    CrossRef
  15. . Recent Advances in Diagnosis and Therapy of Peripheral Neuropathy. The Japanese Journal of Rehabilitation Medicine 2023;60(3):184
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/resprot.6610):

  1. Yadav N, Pragati , Dwivedi MK. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases. 2022. Chapter 9:177
    CrossRef
  2. El-Abassi RN, Soliman M, Levy MH, England JD. Neuromuscular Disorders. 2022. :312
    CrossRef